Business NewsMarketWire • Vernalis Announces Start of CCP-08 12 Month Stability Testing

Vernalis Announces Start of CCP-08 12 Month Stability Testing

Vernalis Announces Start of CCP-08 12 Month Stability Testing

WINNERSH, UNITED KINGDOM--(Marketwired - Oct 12, 2015) - Vernalis plc (LSE: VER) (OTC PINK: VNLPY) announces that its partner, Tris Pharma, has successfully manufactured 3 registration batches of CCP-08 and material from these batches is now up on stability. CCP-08 is the third programme in Vernalis' cough cold pipeline from its exclusive licensing agreement with Tris Pharma. The first product, TuzistraT XR was approved by the FDA on 30 April 2015 and was launched into the US prescription cough cold market on 8 September 2015. 

View More : http://www.marketwired.com/mw/release.do?id=2062914&sourceType=3
Releted News by marketwire
MEDIA ALERT: Pegasystems to Host Executive Roundtable at Sibos 2015 on How Banks Are Transforming KYC to Meet Complex Global Regulatory Requirements While Improving Onboarding Time & Customer Experience
Vernalis Announces Start of CCP-08 12 Month Stability Testing